Is it safe?
Can SNDX take a bad year?
Syndax Pharmaceuticals, Inc. holds $2.1M more cash than debt, so a bad year is a question about profits, not about lenders.
$2.1M
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Altman Z-score
- -2.17
Altman Z-score · distress zone, below 1.8
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
Details›
- Total debtQ1 2026
- $350M
- Cash and short-term investments
- $352M
- Net cash
- $2.1M
- Operating profit, trailing twelve months
- −$224M
- Debt / equity
- 8.41×
- Annualised volatilitytwo years of daily moves
- 62%
- Worst drawdown on file
- −79%
- Below its 52-week high
- −20%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.